Katie Drummond: right. Like I've said a lot on wired over the past few months, I move fast and break things. When we come back we will take a little break from what you need to read wired today.
please A creepy valley. I'm Katie Drummond, global editorial director at Wired. Joined by Zoë Schiffer, director of business and industry at Wired. Now, before I let you go, tell our listeners that we absolutely have to read, and with the exception of the stories we told in this episode, you need to read today on Wired.com.
Zoe Schiffer: got it. I wish I had a lovely, fun, uplifting story to tell you, but I have another fate and dark story, and it is
Katie Drummond: Awshucks.
Zoe Schiffer: know. It was by our freelancer Caroline Haskins and he has actually announced that she will be joining the business desk. It's very exciting. She's incredible. She is very good. i'm so excited. And she wrote an article yesterday about Trump and Elon Musk's FDA cuts. So another administration, which has experienced tight budgets and staffing cuts, has already put drug development at risk. And she received this from a dozen second submissions from the pharmaceutical company.
Katie Drummond: So between these SEC filings and what you and Emily reported on these credit cards freezes yesterday, we certainly seem to be based on stopping here in some really consequential ways.
Zoe Schiffer: Yeah. So it's interesting because the pharmaceutical companies, which are pharmaceutical companies, don't say, “The FDA doesn't approve our drugs, so these drugs can't be put on the market.” They say that when you're talking about drugs or drugs, this agency is already designing a very slow movement because the interests are so high. And then there were reductions in staffing and budget cuts. The worry is that this will stop. And if you're a pharmaceutical company behind the development of new drugs that are already approved, or putting a lot of time, energy, resources and new drug development that you're not sure will get FDA approval, then all of a sudden you can see something like that. And it has really serious implications for those who may need these new treatments.
Katie Drummond: Zoe, thank you for all the joys we bring to our show today. Thank you for participating. It's really, really appealing and I'm very grateful for your report and the team's report.
Zoe Schiffer: Thank you for welcoming me.
Katie Drummond: That's our show today. Link to all the stories we talked about today and link them in our show notes. Be sure to check out Thursday's episode A creepy valleythis is all about the pronatalist movement in Silicon Valley. If you like what you heard today, follow the show and rate it on your chosen podcast app. If you would like to contact someone who will show you questions, comments, or suggestions, please write to uncannyvalley@wired.com.
Macro sound Amalral mixed this episode. Jake Lummus is our studio engineer. Jordan Bell is our executive producer and Chris Bannon is our global audio director at Condé Nast. And I'm Katie Drummond, global editorial director at Wired.
Goodbye.
